Acrivon Therapeutics, Inc. (ACRV)
NASDAQ:ACRV
Want to see ACRV full AI Analyst Report?
ACRV Stock Chart & Stats
$1.78
-$0.20(-3.17%)
At close: 4:00 PM EST
$1.78
-$0.20(-3.17%)
Day’s Range― - ―
52-Week Range$1.15 - $3.56
Previous CloseN/A
Volume1.72K
Average Volume (3M)996.44K
Market Cap
$60.78M
Enterprise Value$18.84M
Total Cash (Recent Filing)$97.74M
Total Debt (Recent Filing)$2.42M
Price to Earnings (P/E)―
Beta1.84
Next Earnings
Aug 19, 2026EPS Estimate
-0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.00
Shares Outstanding42,801,727
10 Day Avg. Volume442,853
30 Day Avg. Volume996,436
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)0.82
Price to Sales (P/S)0.00
P/FCF Ratio-1.42
Enterprise Value/Market Cap0.31
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit82.64
Enterprise Value/Ebitda-0.22
Forecast
1Y Price Target
$12.00Price Target Upside574.16% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-2.07
Revenue Forecast (FY)$1.31M
Bulls Say, Bears Say
Bulls Say
Precision Diagnostics PlatformOwning the AP3 predictive proteomics platform and a CLIA-certified lab creates durable differentiation. It enables biomarker-driven patient selection, de-risks development pathways, supports companion diagnostics and partnership value, and can accelerate targeted approvals and commercial adoption over time.
Promising Registrational-intent Clinical DataA strong, subtype-specific response signal in a registrational-intent Phase 2b materially increases the chance of a focused regulatory path and commercial differentiation. Positive, reproducible efficacy in a high-unmet-need indication supports long-term franchise potential if later-phase results confirm benefit.
Conservative Leverage And RunwayMinimal debt reduces bankruptcy and interest risks while a multi-quarter cash runway affords time to progress registrational trials and seek strategic partnerships or non-dilutive options. This financial buffer supports execution of clinical milestones without immediate financing pressure.
Bears Say
Persistent Cash BurnSustained negative operating and free cash flow means the business depends on external capital to fund R&D and trials. Over the medium term this creates dilution risk, constrains strategic optionality, and forces management to prioritize capital-efficient programs over broader pipeline investments.
Eroding Equity BaseA meaningful drop in shareholders' equity reflects accumulated deficits and weak returns. This weakens balance-sheet flexibility for future financings or partnerships, increases reliance on dilutive raises, and signals a longer path to self-funded commercialization absent successful approvals or deals.
Clinical And Execution RiskAs a clinical-stage oncology company, outcomes hinge on trial execution, enrollment, and confirmatory data. Failures or delays can negate current progress, extend cash burn, and delay commercialization, making long-term value highly contingent on successful late-stage results and regulatory approvals.
Acrivon Therapeutics, Inc. News
ACRV FAQ
What was Acrivon Therapeutics, Inc.’s price range in the past 12 months?
Acrivon Therapeutics, Inc. lowest stock price was $1.15 and its highest was $3.56 in the past 12 months.
What is Acrivon Therapeutics, Inc.’s market cap?
Acrivon Therapeutics, Inc.’s market cap is $60.78M.
When is Acrivon Therapeutics, Inc.’s upcoming earnings report date?
Acrivon Therapeutics, Inc.’s upcoming earnings report date is Aug 19, 2026 which is in 70 days.
How were Acrivon Therapeutics, Inc.’s earnings last quarter?
Acrivon Therapeutics, Inc. released its earnings results on May 13, 2026. The company reported -$0.49 earnings per share for the quarter, beating the consensus estimate of -$0.525 by $0.035.
Is Acrivon Therapeutics, Inc. overvalued?
According to Wall Street analysts Acrivon Therapeutics, Inc.’s price is currently Undervalued.
Does Acrivon Therapeutics, Inc. pay dividends?
Acrivon Therapeutics, Inc. does not currently pay dividends.
What is Acrivon Therapeutics, Inc.’s EPS estimate?
Acrivon Therapeutics, Inc.’s EPS estimate is -0.5.
How many shares outstanding does Acrivon Therapeutics, Inc. have?
Acrivon Therapeutics, Inc. has 42,801,727 shares outstanding.
What happened to Acrivon Therapeutics, Inc.’s price movement after its last earnings report?
Acrivon Therapeutics, Inc. reported an EPS of -$0.49 in its last earnings report, beating expectations of -$0.525. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Acrivon Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ACRV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Acrivon Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$12.00 (574.16% Upside)
$12.00 (574.16% Upside)
Hedge Fund Trend
Decreased
By 22.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 3.0%
Last 30 Days ▼ 3.0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-62.55%
12-Months-Change
Fundamentals
Return on Equity
-64.43%
Trailing 12-Months
Asset Growth
-38.85%
Trailing 12-Months
Company Description
Acrivon Therapeutics, Inc.
Acrivon Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company primarily focused on creating oncology treatments. The firm employs a unique strategy to identify patients whose tumors are predicted to be sensitive to specific medications, utilizing its proprietary proteomics-based platform for patient identification. This advanced system, named Acrivon Predictive Precision Proteomics (AP3), serves as a precision medicine tool. It is instrumental in developing drug-specific OncoSignature companion diagnostics, which are designed to pinpoint individuals most likely to benefit from the company's therapeutic candidates. Acrivon's flagship clinical asset is ACR-368, a selective small molecule inhibitor that targets both CHK1 and CHK2. This candidate is currently undergoing a potentially pivotal Phase 2 trial for a range of advanced tumor types, notably including platinum-resistant ovarian, endometrial, and bladder cancers. Beyond its lead program, the company is also cultivating several early-stage pipeline programs. These initiatives concentrate on crucial regulatory points within the DNA damage response and cell cycle regulation pathways, specifically identifying targets such as the protein kinases WEE1 and PKMYT1. Established in 2018, Acrivon Therapeutics, Inc. maintains its headquarters in Watertown, Massachusetts.
ACRV Stock 12 Month Forecast
Average Price Target
$12.00
▲(574.16% Upside)
Technical Analysis
Medicinova
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Immix Biopharma
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
35.82% Insiders
2.57% Mutual Funds
25.02% Other Institutional Investors
34.68% Public Companies and Individual Investors
Options Prices
Currently, No data available
---